Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Rad51/BRCA2 disruptors inhibit homologous recombination and synergize with olaparib in pancreatic cancer cells.

Roberti M, Schipani F, Bagnolini G, Milano D, Giacomini E, Falchi F, Balboni A, Manerba M, Farabegoli F, De Franco F, Robertson J, Minucci S, Pallavicini I, Di Stefano G, Girotto S, Pellicciari R, Cavalli A.

Eur J Med Chem. 2019 Mar 1;165:80-92. doi: 10.1016/j.ejmech.2019.01.008. Epub 2019 Jan 10.

PMID:
30660828
2.

Epigallocatechin-3-gallate and 6-OH-11-O-Hydroxyphenanthrene Limit BE(2)-C Neuroblastoma Cell Growth and Neurosphere Formation In Vitro.

Farabegoli F, Govoni M, Spisni E, Papi A.

Nutrients. 2018 Aug 22;10(9). pii: E1141. doi: 10.3390/nu10091141.

3.

Synthetic Lethality Triggered by Combining Olaparib with BRCA2-Rad51 Disruptors.

Falchi F, Giacomini E, Masini T, Boutard N, Di Ianni L, Manerba M, Farabegoli F, Rossini L, Robertson J, Minucci S, Pallavicini I, Di Stefano G, Roberti M, Pellicciari R, Cavalli A.

ACS Chem Biol. 2017 Oct 20;12(10):2491-2497. doi: 10.1021/acschembio.7b00707. Epub 2017 Sep 1.

PMID:
28841282
4.

EGFR inhibition by (-)-epigallocatechin-3-gallate and IIF treatments reduces breast cancer cell invasion.

Farabegoli F, Govoni M, Spisni E, Papi A.

Biosci Rep. 2017 May 17;37(3). pii: BSR20170168. doi: 10.1042/BSR20170168. Print 2017 Jun 30.

5.

Epigallocatechin-3-gallate Increases RXRγ-mediated Pro-apoptotic and Anti-invasive Effects in Gastrointestinal Cancer Cell Lines.

Papi A, Govoni M, Ciavarella C, Spisni E, Orlandi M, Farabegoli F.

Curr Cancer Drug Targets. 2016;16(4):373-85.

PMID:
26278714
6.

A RXR ligand 6-OH-11-O-hydroxyphenanthrene with antitumour properties enhances (-)-epigallocatechin-3-gallate activity in three human breast carcinoma cell lines.

Farabegoli F, Govoni M, Ciavarella C, Orlandi M, Papi A.

Biomed Res Int. 2014;2014:853086. doi: 10.1155/2014/853086. Epub 2014 Jun 11.

7.

Vitexin-2-O-xyloside, raphasatin and (-)-epigallocatechin-3-gallate synergistically affect cell growth and apoptosis of colon cancer cells.

Papi A, Farabegoli F, Iori R, Orlandi M, De Nicola GR, Bagatta M, Angelino D, Gennari L, Ninfali P.

Food Chem. 2013 Jun 1;138(2-3):1521-30. doi: 10.1016/j.foodchem.2012.11.112. Epub 2012 Dec 5.

PMID:
23411276
8.

(-)-Epigallocatechin-3-gallate down-regulates EGFR, MMP-2, MMP-9 and EMMPRIN and inhibits the invasion of MCF-7 tamoxifen-resistant cells.

Farabegoli F, Papi A, Orlandi M.

Biosci Rep. 2011 Apr;31(2):99-108. doi: 10.1042/BSR20090143.

PMID:
20446926
9.

(-)-Epigallocatechin-3-gallate downregulates estrogen receptor alpha function in MCF-7 breast carcinoma cells.

Farabegoli F, Barbi C, Lambertini E, Piva R.

Cancer Detect Prev. 2007;31(6):499-504.

PMID:
18061364
10.

Simultaneous chromosome 1q gain and 16q loss is associated with steroid receptor presence and low proliferation in breast carcinoma.

Farabegoli F, Hermsen MA, Ceccarelli C, Santini D, Weiss MM, Meijer GA, van Diest PJ.

Mod Pathol. 2004 Apr;17(4):449-55.

11.

Retention of the p53 codon 72 arginine allele is associated with a reduction of disease-free and overall survival in arginine/proline heterozygous breast cancer patients.

Bonafé M, Ceccarelli C, Farabegoli F, Santini D, Taffurelli M, Barbi C, Marzi E, Trapassi C, Storci G, Olivieri F, Franceschi C.

Clin Cancer Res. 2003 Oct 15;9(13):4860-4.

12.

Genetic pathways in the evolution of breast ductal carcinoma in situ.

Farabegoli F, Champeme MH, Bieche I, Santini D, Ceccarelli C, Derenzini M, Lidereau R.

J Pathol. 2002 Mar;196(3):280-6.

PMID:
11857490

Supplemental Content

Loading ...
Support Center